Manufacturing remains a critical barrier to scaling CGTs, limiting the clinical and commercial impact of this life-saving new class of therapies. Ori Biotech has developed the IRO platform as part of its mission to enable widespread patient access to life-saving CGTs.

“A new wave of cell and gene therapies holds immense promise for patients; however, to achieve the true clinical impact, therapies must be not only approvable but also accessible and affordable,” commented Jason C. Foster, CEO, Ori Biotech. “Over the last five years, we’ve focused on Biology First, generating best-in-class biological data from over 500 runs with ten different partners, across different cell types and protocols to demonstrate how the IRO platform can Automate Better Biology. For too long, scientists and therapy developers have had to sacrifice biological performance for automation, not anymore.”

The IRO platform, with its flexibility for early process development and scalability for GMP manufacturing, provides a seamless transition from R&D to GMP. It automates and standardizes the most labor-intensive parts of the cell and gene therapy manufacturing workflow, reducing labor by up to 70%, cost of goods by up to 50%, and processing times by up to 25%. This acceleration in therapy development could potentially bring products to patients more quickly. Ultimately, IRO aims to empower scientists to optimize their processes, innovate, and help organizations reach their goals faster and at scale.

“I started Ori to support and empower the scientific community to reduce the time and cost to develop and manufacture cell therapies in order to increase patient access,” said Farlan Veraitch, PhD, Founder and CSO, Ori Biotech. “IRO is the first, important step on Ori’s journey to develop innovations that support the heroes of cell therapy who are working so hard to enable widespread patient access to life-saving cell and gene therapies.”